Join to View Full Profile
1415 W Lake StAddison, IL 60101
Phone+1 847-472-2145
Fax+1 847-981-5765
Dr. Baum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Gastroenterology, 1986 - 1989
Tufts Medical CenterResidency, Internal Medicine, 1983 - 1986
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1983
Certifications & Licensure
IL State Medical License 1986 - 2023
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- Personalized Smartphone-Enabled Assessment of Blood Pressure and Its Treatment During the SARS-CoV-2 COVID-19 Pandemic in Patients From the CURE-19 Study: Longitudinal...Leanne Richardson, Nihal Noori, Jack Fantham, Gregor Timlin, James Siddle
JMIR Mhealth and Uhealth. 2024-12-03 - 18 citationsSeasonal patterns of abdominal pain consultations among adults and children.Miguel Saps, Stacie Hudgens, Reema Mody, Karen Lasch, Venkatesh Harikrishnan
Journal of Pediatric Gastroenterology and Nutrition. 2013-03-01 - 134 citationsAge, socioeconomic status and obesity growthCharles L. Baum, Christopher J. Ruhm
Journal of Health Economics. 2009-05-01
Journal Articles
- Effects of 12 Weeks of Treatment with Intravenously Administered Bococizumab, a Humanized Monoclonal Antibody Blocking Proprotein Convertase subtilisin/kexin Type 9, i...Charles M Baum, Sergio Fazio, Cardiovascular Therapeutics
- The Effects of Single‐ and Multiple‐Dose Administration of Bococizumab (RN316/PF‐04950615), a Humanized IgG2Δa Monoclonal Antibody Binding Proprotein Convertase subtil...Charles Baum, MD, Cardiovascular Therapeutics
Press Mentions
Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNovember 7th, 2022- Mirati's Adagrasib Spurs 41% Response in Pancreatic, GI Tumors, Scoring Points Where KRAS Leader Amgen Hasn't GoneJanuary 21st, 2022
- Mirati Gives First Look at KRAS Drug Combination in Lung CancerNovember 8th, 2021
- Join now to see all
Industry Relationships
- Vice President, TakedaHead of US medical and scientific affairs2006 - 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
